Patents Examined by Timothy P Thomas
  • Patent number: 10653674
    Abstract: There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin, which compounds include substituted pyrazolyl or substituted triazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing a disease or disorder, which disease or disorder is amenable to treatment or prevention by the inhibition of thrombin.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: May 19, 2020
    Assignee: VERSEON CORPORATION
    Inventors: Kevin Michael Short, Son Minh Pham, David Charles Williams, Somalee Datta
  • Patent number: 10639281
    Abstract: The present disclosure relates to an oral, immediate release, abuse deterrent pill containing at least one active pharmaceutical ingredient susceptible to abuse which is homogenously spread throughout a carrier matrix used to deter abuse. The pill is prepared using hot melt extrusion and a forming unit through a continuous process. The formed pill is abuse deterrent to parenteral administration due at least to particle size, viscosity, or purity limitations.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: May 5, 2020
    Assignee: Pharmaceutical Manufacturing Research Services, Inc.
    Inventors: Edwin R. Thompson, Eric R. Thompson, Nicholas R. Myslinski, Steven F. Kemeny
  • Patent number: 10632105
    Abstract: The invention relates to the selective targeting of specific ?2 adrenergic receptor subtypes for facilitating and also restoring standing and walking in a subject affected by spinal cord disorders, in particular spinal cord injury. In particular, the improvement of locomotion by targeting specific receptor subtypes can be achieved by stimulation of the ?2c receptor subtype using an ?2c specific agonist or by blocking the ?2a receptor subtype using ?2a antagonists. A combination of an ?2c agonist and an ?2a antagonist is also provided for a synergistic effect. Alternatively, a large ?2 agonist can be used in combination with an ?2a antagonist to achieve specific stimulation of the ?2c receptor. Pharmaceutical compositions, kit-of-parts and therapeutic systems comprising said agonists/antagonists as active agents are objects of the present invention.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: April 28, 2020
    Assignee: ÉCOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL)
    Inventors: Grégoire Courtine, Quentin Barraud, Pavel Musienko
  • Patent number: 10632083
    Abstract: Provided herein is an ophthalmic composition including a therapeutic active agent and an anti-inflammatory agent, in which the active agent is at least about 0.01% w/v of chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof. Methods for treating or preventing ocular disease or infection in a subject in need thereof are also provided. The method may include administering to an eye of a subject an ophthalmic composition including chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof, and an anti-inflammatory agent. The chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof and the anti-inflammatory agent are present in an amount effective to treat or prevent the ocular disease or infection in a subject in need thereof.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: April 28, 2020
    Assignee: SaCSh Corp.
    Inventor: Uri Shabto
  • Patent number: 10624339
    Abstract: There is provided a method of controlling filbertworm capable of reducing the number of release positions without changing a dosage amount per unit area. More specifically, there is provided a method of controlling filbertworm comprising the step of: providing E,E-8,10-dodecadienyl acetate or a composition comprising 80% by weight or more of E,E-8,10-dodecadienyl acetate at 1 to 100 release positions/ha to release the E,E-8,10-dodecadienyl acetate at a release rate of from 0.01 to 5 g/day/ha for mating disruption.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: April 21, 2020
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Tatsuya Hojo, Erina Ohno, Naoki Ishibashi
  • Patent number: 10626126
    Abstract: There are provided 5,6-dihydro-4H-dithieno[3,2-b:2?,3?-d]azepine derivatives(as defined in the disclosure) which are useful in the treatment of RSV infection and for the prevention of disease associated with RSV infection.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: April 21, 2020
    Assignee: PULMOCIDE LIMITED
    Inventors: Simon Fraser Hunt, Stuart Thomas Onions, Vladimir Sherbukhin, Euan Alexander Fraser Fordyce, Jennifer Claire Thomas, Peter John Murray, Matthew Stephen Coates, Daniel William Brookes, Kazuhiro Ito, Peter Strong
  • Patent number: 10617695
    Abstract: Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: April 14, 2020
    Assignee: Vistakon Pharmaceuticals, LLC
    Inventors: Avner Ingerman, Frans Janssens, Anton Megens, Mark B. Abelson
  • Patent number: 10610499
    Abstract: Provided herein is an ophthalmic composition including a therapeutic active agent and an anti-inflammatory agent, in which the active agent is at least about 0.01% w/v of chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof. Methods for treating or preventing ocular disease or infection in a subject in need thereof are also provided. The method may include administering to an eye of a subject an ophthalmic composition including chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof, and an anti-inflammatory agent. The chlorhexidine, derivatives, or analogues of chlorhexidine, or a pharmaceutically acceptable salt, solvent, hydrate, or polymorph thereof and the anti-inflammatory agent are present in an amount effective to treat or prevent the ocular disease or infection in a subject in need thereof.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: April 7, 2020
    Assignee: SaCSh Corp.
    Inventor: Uri Shabto
  • Patent number: 10597606
    Abstract: A method for producing monovalent unsaturated free fatty acids having 20 and/or 22 carbons or low-grade alcohol esters thereof, said method involving the following: obtaining free fatty acids or low-grade alcohol esters through the hydrolysis or alcoholysis of oils and fats derived from marine products; carrying out distillation on the free fatty acids or low-grade alcohol esters, and reducing the concentration of fatty acids with 18 or less carbons in the low-grade alcohol esters or free fatty acids; and collecting fractions of monovalent unsaturated free fatty acids having 20 and/or 22 carbons or low-grade alcohol esters thereof by column chromatography based on reversed-phase distribution.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: March 24, 2020
    Assignee: Nippon Suisan Kaisha, Ltd.
    Inventors: Seizo Sato, Takuro Fukae, Naomi Ohtsuka, Hideaki Yamaguchi
  • Patent number: 10576038
    Abstract: Provided are a reducible degradable hyperbranched-polymer nanomicelle and a method for preparation thereof and an application thereof. Cystamine and polyethylene glycol diglycidyl ether are polymerized by means of a nucleophilic addition mechanism; in one step, a hyperbranched polymer alternatingly arising from cystamine and polyethylene glycol structural units is synthesized and obtained; then, a hyperbranched nanomicelle is formed by means of self-assembly during the process of dialysis. The hyperbranched-polymer chain segments contain both tertiary aminos and disulfide bond structural units and have pH- and reduction responsiveness, and the hyperbranched three-dimensional cavity structure imparts a drug-carrying ability to the nanomicelle.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: March 3, 2020
    Assignee: JIANGNAN UNIVERSITY
    Inventors: Caihua Ni, Yamin Zhou, Liping Zhang, Gang Shi
  • Patent number: 10576077
    Abstract: The present disclosure relates to the preparation of polymorphic mixtures of Cepharanthine.2HCl. Mixtures of at least two polymorphic forms can be formed into a mobile liquid phase in organic/aqueous solvent mixtures along with enteric polymer that can be spray dried to produce solid particulate enteric formulations for medicinal drug-treatment applications.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: March 3, 2020
    Assignee: Southwest Research Institute
    Inventors: William E. Bauta, Joseph A. McDonough, Hong Dixon, Stephen T. Wellinghoff, Kevin Fitzpatrick
  • Patent number: 10570095
    Abstract: 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is useful in the modulation of blood or serum uric acid levels. In some embodiments, 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is used in the treatment or prevention of disorders related to aberrant levels of uric acid. In some embodiments, 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid is used for reducing serum uric acid levels in a human. Also described herein are compositions comprising 2-((3-(4-cyanonaphthalen-1-yl)pyridin-4-yl)thio)-2-methylpropanoic acid, and their use in the modulation of blood or serum uric acid levels.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: February 25, 2020
    Assignee: Ardea Biosciences, Inc.
    Inventors: Li-Tain Yeh, Barry D. Quart
  • Patent number: 10557850
    Abstract: The present invention provides methods of treating cancer by administering an IL8-CXCR1 pathway inhibitor (e.g., an anti-CXCR1 antibody or Repertaxin) alone or in combination with an additional chemotherapeutic agent such that non-tumorigenic and tumorigenic cancer cells in a subject are killed. The present invention also provides compositions and methods for detecting the presence of and isolating solid tumor stem cells in a patient (e.g., based on the presence of CXCR1 or FBXO21).
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: February 11, 2020
    Assignee: THE REGENTS OF UNIVERSITY OF MICHIGAN
    Inventors: Max S. Wicha, Christophe Ginestier
  • Patent number: 10548873
    Abstract: Plant phenols, in particular, plant phenolic acids, like rosmarinic acid, ellagic acid, and chlorogenic acid, are used in the treatment or prevention of eosinophilic esophagitis.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: February 4, 2020
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Carine Blanchard, Sebastien Holvoet
  • Patent number: 10532102
    Abstract: The present invention provides compositions or formulations comprising the combination of a compound of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione or a salt thereof or hydrate of the foregoing, and a cyclodextrin; or in further combination with an excipient comprising L-Arginine or other additives, wherein the compositions or formulations increases water solubility and oral bioavailability of 5-[3-(4-benzyloxyphenylthio)-fur-2-yl]-imidazolidin-2,4-dione and its related compounds. The method of making or using the compositions or formulations is also disclosed. Such compositions or formulations may be used in treatment of certain diseases including asthma through inhibition of matrix metalloproteinase-12.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: January 14, 2020
    Assignee: Foresee Pharmaceuticals Co., Ltd.
    Inventors: Yuhua Li, ChiaTing Huang, John Mao
  • Patent number: 10532079
    Abstract: Extracts or beverages whose ratio between the content of 2,5-piperazinedione,3,6-bis(phenylmethyl)-,(3S,6S)-(unit: ?g/100 g) and Brix (Bx) is 6 (?g/100 g)/Bx or more are good in flavor and feeling on the tongue and further have a good appearance.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: January 14, 2020
    Assignees: SUNTORY HOLDINGS LIMITED, SUNTORY BEVERAGE & FOOD ASIA PTE. LTD.
    Inventors: Hideki Matsubayashi, Kenji Yamamoto, Hiroshi Watanabe, Lee Kian Hong
  • Patent number: 10525009
    Abstract: The present invention provides improved formulations of 6-mercaptopurine that exhibit better bioavailability and faster dissolution than previous formulations.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: January 7, 2020
    Assignee: Hadasit Medical Research Services and Development Ltd.
    Inventors: Itzhak E. Lerner, Moshe Flashner-Barak, Erwin v Achthoven, Hans Keegstra, Ruud Smit
  • Patent number: 10512621
    Abstract: Embodiments disclosed herein generally relate to methods of treating posttraumatic stress disorder (PTSD) using acamprosate formulations and/or acamprosate formulations in combination with at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: December 24, 2019
    Assignee: Synchroneuron, Inc.
    Inventors: Barry S. Fogel, William D. Kerns, Kei-Lai Fong
  • Patent number: 10507209
    Abstract: The invention relates to quinazoline derivatives substituted by aniline which are represented by the below formula (I), pharmaceutical acceptable salts and stereoisomer thereof, wherein these groups of R1, R2, R3, R4, R5, R6, L and n have the meanings given in the specification. The invention also relates to preparation methods, pharmaceutical compositions, pharmaceutical preparation and the use for preparation of medicine of treating excessive hyperplasia and chronic obstructive pulmonary disease and uses for treating excessive hyperplasia and chronic obstructive pulmonary disease thereof.
    Type: Grant
    Filed: August 7, 2017
    Date of Patent: December 17, 2019
    Assignee: XUANZHU PHARMA CO, LTD.
    Inventors: Yanyan Dong, Chengkon Shih
  • Patent number: 10500281
    Abstract: What is disclosed is a semi-solid controlled release pharmaceutical composition containing biocompatible and bioerodible semi-solid lipid matrix incorporating local anesthetics agents to form a semi-solid solution, a method of using the pharmaceutical composition to treat, and a method of making the pharmaceutical composition.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: December 10, 2019
    Assignee: Mira Pharma Corporation
    Inventors: Hui Rong Shen, Na Gan